Higher doses of eculizumab may be beneficial in paroxysmal nocturnal haemoglobinuria in pregnancy
Pregnant patients with classical paroxysmal nocturnal haemoglobinuria need individualised treatment and frequent monitoring.Even with appropriate terminal complement blockade, pregnant patients may have significant breakthrough haemolysis burden, likely due to C3b mediated opsonisation.Higher than standard doses of eculizumab may help control breakthrough haemolysis in pregnant patients.
Authors
- Hemasri Tokala (ORCID: https://orcid.org/0009-0002-4881-863X)
- Ayema Haque (ORCID: https://orcid.org/0000-0002-6479-3033)
- Vanita Motiani
- Harshank Vishnubhai Patel
- Akshay Amaraneni (ORCID: https://orcid.org/0000-0002-3231-6056)
- Steven Stone (ORCID: https://orcid.org/0009-0007-8231-356X)
- M. Laird
Institutions
- Bronson Methodist Hospital (US)
- University of Arizona (US)
- Western Michigan University (US)
- Kalamazoo Psychiatric Hospital (US)
- Banner - University Medical Center Tucson (US)
- Borgess Health (US)
- Stryker (United States) (US)
Publication Details
- Journal
- European Journal of Case Reports in Internal Medicine
- Published
- 2025-09-01
- DOI
- https://doi.org/10.12890/2025_005721
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00